How Will FDA’s Pivot to Overall Survival Affect Cancer Drug Development?

The progression-free survival metric has helped shepherd many products across the regulatory finish line. Experts say the FDA’s new emphasis on overall survival will be felt especially by small biotechs.

Scroll to Top